Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.60 |
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7725121 | 0.92 | BACE1 (0.55) | PTPN1BACE1APPALOX5THRA | |
| SCHEMBL7734908 | 0.89 | PTPN1 (0.48) | PTPN1BACE1APPALOX5OR51E2 | |
| SCHEMBL10704484 | 0.86 | PTPN1 (0.46) | PTPN1BACE1APPALOX5OR51E2 | |
| SCHEMBL3685390 | 0.85 | CCNC (0.58) | PTPN1BACE1APPALOX5OR51E2 | |
| SCHEMBL9202609 | 0.85 | ALDH1A1 (0.59) | PTPN1BACE1THRATHRBEGFR | |
| SCHEMBL12646568 | 0.82 | HCAR2 (0.55) | PTPN1APPALDH1A1 | |
| SCHEMBL12646541 | 0.82 | PTPN1 (0.55) | PTPN1CNR2 | |
| SCHEMBL15823895 | 0.82 | PTPN1 (0.59) | PTPN1APPSIRT2ALDH1A1GAA | |
| SCHEMBL5039715 | 0.81 | PTPN1 (0.55) | PTPN1SIRT2CNR2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27753206 | 0.81 | PTPN1 (0.58) | PTPN1APPSIRT2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303333-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2019-11-20 | — | — | EP | disclosed |
| US-9662323-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-30 | — | — | US | disclosed |
| US-9662323-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-30 | — | — | US | disclosed |
| US-20160346271-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-01 | — | — | US | disclosed |
| US-20160346271-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-01 | — | — | US | disclosed |
| CN-1103332-C | Biphenyl-5-alkanoic acid derivs. and use thereof | ASAHI CHEMICAL IND (JP) | 2003-03-19 | — | — | CN | disclosed |
| US-6376546-B1 | ANTIALLERGENS | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-04-23 | — | — | US | disclosed |
| CN-1276778-A | Biphenyl-5-alkanoic acid derivs. and use thereof | ASAHI CHEMICAL IND (JP) | 2000-12-13 | — | — | CN | disclosed |
| EP-1024130-A1 | BIPHENYL-5-ALKANOIC ACID DERIVATIVES AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346271-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | PTPN1 3700/4885BACE1 1151/4885APP 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.